The Lead Episode 142: A Discussion of Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort-The Lead Episode 142 Speaker Information

The Lead Episode 142 Speaker Information

Pdf Summary

This document announces a journal discussion focused on the safety and clinical outcomes of Class 1c antiarrhythmic therapy after percutaneous coronary intervention (PCI) in patients with new-onset atrial fibrillation. The featured article—titled <em>“Class 1c Antiarrhythmic Therapy Following PCI in New Onset Atrial Fibrillation: Safety and Clinical Outcomes from a Nationwide Cohort”</em>—was published in <em>Heart Rhythm Journal</em> and authored by Ting-Chun Huang and colleagues (including Po-Hsueh Su, Hui-Wen Lin, Po-Tseng Lee, Yu Liao, Chao-Yu Chen, Li-Hao Yap, Sheng-Hsiang Lin, and Yi-Heng Li).

The session is hosted by Deep Chandh Raja (MBBS, MD, PhD) from the Australian National University and Kauvery Hospital. Two additional contributors are listed: Deepak Padmanabhan (MD, FHRS) from Narayana Institute of Cardiac Sciences in Bengaluru, and Sandeep Gautam (MD, MPH, FHRS) from the University of Missouri Health.

The document also provides conflict-of-interest disclosures. Deep Chandh Raja and Deepak Padmanabhan report no disclosures. Sandeep Gautam reports honoraria and speaking/teaching/consulting relationships with Biosense Webster, and fellowship support from Medtronic, Inc. and Abbott.

The document concludes with a brief “Thank you,” indicating it is likely a title slide or introductory page for the discussion session.

Keywords

Class 1c antiarrhythmic therapy

percutaneous coronary intervention (PCI)

new-onset atrial fibrillation

safety outcomes

clinical outcomes

nationwide cohort study

Heart Rhythm Journal

journal discussion session

conflict of interest disclosures

Biosense Webster Medtronic Abbott